Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B

Journal of Viral Hepatitis

Volumn 12, Issue 3, 2005, Pages 262-268

  Yurdaydin, Cihan ^a   Bozkaya, H ^b   Cetinkaya H ^b   Sahin T ^b   Karaoguz D ^b   Toruner M ^b   Erkan, O ^b   Heper, A O ^b   Erden, E ^b   Bozdayi, A M ^b   Uzunalimoglu O ^b  

^a ANKARA UNIVERSITY   (Turkey)

^b NONE

Author keywords

Antiviral treatment; HBeAg( ) chronic hepatitis B; Lamivudine; Lamivudine interferon combination; YMDD mutants

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT VIRUS INFECTION; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS MUTANT;

ADOLESCENT; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; LAMIVUDINE; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROBABILITY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 21044441005     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00566.x     Document Type: Article

References (36)

1. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-353.
2. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B. N Engl J Med 1999; 341: 1256-1263.
3. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68.
4. Marcellin P, Chang T-T, Lim SG et al. Adevofir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816.
5. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adevofir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-807.
6. Lok ASF, Heathcote EJ, Hoofnagle JH. Management of hepatitis B, 2000: summary of a workshop. Gastroenterology 2001; 120: 1828-1853.
7. Bryant ML, Bridges EG, Placidi L et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001; 45: 229-235.
8. Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: the final solution? Hepatology 2000; 32: 430-432.
9. Di Bisceglie AM. Combination therapy for hepatitis B. Gut 2002; 50: 443-445.
10. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34: 1225-1241.
11. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617-624.
12. Rizetto M. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. J Med Virol 2002; 66: 435-451.
13. Brunetto MR, Giarin M, Saracco G et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993; 105: 845-850.
14. Fattovich G, Farci P, Rugge M et al. A randomized controlled trial lympoblastoid interferon-α in patients with chronick hepatitis B lacking HBeAg. Hepatology 1992; 15: 584-589.
15. Olivieri F, Santantonio T, Bellati G et al. Long term response to therapy of chronic anti-HBe-positive hepatitis B is por independent of type and schedule of interferon. Am J Gastroenterol 1999; 94: 1366-1372.
16. Lampertico P, Del Ninno E, Manzin A et al. A randomized, controlled clinical trial of a 24 month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997; 26: 1621-1625.
17. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alfa treated and untreated patients with HBeAg negative chronic hepatitis B. J Hepatol 2001; 34: 306-313.
18. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32: 300-306.
19. Hadziyannis SJ, Papatheodoridis GV, EDimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with HBeAg negative chronic hepatitis B. Hepatology 2000; 32: 847-851.
20. Schalm SW, Heathcote J, Cianciara J et al. for the International Lamivudine Study Group. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 562-568.
21. Barbaro G, Zechini F, Pellicelli AM et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol 2001; 35: 406-411.
22. Santantonio T, Niro GA, Sinisi E et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002; 36: 799-804.
23. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
24. Bozkaya H, Yurdaydm C, Bozdayi AM, Erkan Ö, Karayalçin S, Uzunalimoǧlu Ö. Oral ganciclovir for treatment of lamivudine-resistant hepatitis B virus infection: a pilot study. Clin Infect Dis 2002; 35: 960-965.
25. Pawlotsky J-M. Molecular diagnosis of viral hepatitis. Gastroenterology 2002; 122: 1554-1568.
26. Boni C, Bertoletti A, Penna A et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968-975.
27. 7 Sung JJY, Chan HLY, Hui AY et al. Combination of pegylated interferon and lamivudine is superior to lamivudine monotherapy in the treatment of chronic hepatitis B - a randomized trial (abstr.). J Hepatol 2003; 38(Suppl. 2): 33.
28. Scotto G, Fazio V, Campanozzi F, D'Adduzio A. Efficacy of treatment with lamivudine in patients with chronic active e-minus variant hepatitis B virus infection: a non-randomized, open label study. Curr Ther Res 2000; 61: 321-330.
29. Tassopoulos NC, Volpes R, Pastore G et al. Post lamivudine treatment follow-up of patients with HBeAg negative chronic hepatitis B (abstr.). J Hepatol 1999; 30(Suppl. 2): 113.
30. Bozdayi AM, Bozkaya H, Türkyiimaz AR et al. Nucletide divergences in the core promoter and precore region of genotype D hepatitis B virus in patients with persistently elevated or normal ALT levels. J Clin Virol 2001; 21: 91-101.
31. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alfa-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761-763.
32. Perillo RP, Lai C-L, Liaw Y-F et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186-194.
33. Tillmann HL, Wedemeyer H, Bock CT et al. The INNO-LIPA HBV-DR assay is superior to sequencing for the detection of YMDD-mutants (abstract). J Hepatol 2003; 38(Suppl. 2): 176.
34. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 219-226.
35. Yuen M-F, Sablon E, Hui C-K, Yuan H-J, Decraemer H, Lai C-L. Factors associated with hepatitis B virus DNA break-through in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34: 785-791.
36. Stuyver L, Van Geyt C, De Gent S et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000; 38: 702-707.